A new alternative: inhibiting complement activation in patients with IgA nephropathy

Jürgen Floege

doi:10.1016/j.kint.2023.10.012

A new alternative: inhibiting complement activation in patients with IgA nephropathy

Kidney Int. 2024 Jan;105(1):28-30. doi: 10.1016/j.kint.2023.10.012.

Author

Jürgen Floege¹

Affiliation

¹ Division of Nephrology and Immunology, RWTH University of Aachen, Aachen, Germany. Electronic address: jfloege@ukaachen.de.

PMID: 38182298
DOI: 10.1016/j.kint.2023.10.012

Abstract

Mesangial complement C3 deposits, reflecting alternative and possibly lectin pathway activation, are characteristic in biopsies of patients with IgA nephropathy (IgAN). A recent randomized controlled trial tested the efficacy and safety of iptacopan, a factor B inhibitor, in patients with IgAN. Iptacopan dose-dependently reduced proteinuria, and there was a pronounced decrease of urinary C5b-9. This offers the perspective of "personalizing" therapy, which would be a unique feature of this novel approach to IgAN. A phase III clinical trial (APPLAUSE-IgAN) is ongoing.

Publication types

Comment

MeSH terms

Biopsy
Complement Activation
Complement Factor B
Glomerular Mesangium
Glomerulonephritis, IGA* / drug therapy
Humans

Substances

Complement Factor B